LPT funds further five research projects with CCLG worth £520,000.00

 

Little Princess Trust and CCLG partnership funds new research projects into childhood and teenage & young adult cancers

We are pleased to announce that – thanks to the fantastic support of our fundraisers -The Little Princess Trust has funded five new research projects, looking at neuroblastoma, leukaemia and teenage and young adult brain tumours.

 

Earlier this year, in partnership with CCLG, we invited researchers to apply for grants to fund scientific proposals that studied particular areas of childhood cancer, including studies which will help us to better understand the causes of childhood cancer, and studies that may lead to new approaches to treatment, especially ‘kinder’ treatments – those that might lead to a reduction in side effects

Following rigorous review by CCLG’s Research Advisory Group, the Little Princess Trust committed to funding five further research studies, with a combined value of just over £520,000.

The following projects were funded:

  • A study led by Prof Deb Tweddle at Newcastle University, looking at the genetics of some intermediate-risk neuroblastomas which have poorer outcomes, to see what characteristics these tumours share with high-risk tumours, and whether more intensive treatment would improve the prognosis for children with this disease.
  • A project led by Dr Karim Malik at the University of Bristol, investigating whether some proteins on relapsed neuroblastoma cells may be targets for drugs, that could help us overcome drug resistance. This resistance to drugs is common in relapsed disease, making it much more challenging to treat, with poorer outcomes for children.
  • A study led by Dr Anbarasu Lourdusamy at the University of Nottingham aims to comprehensively characterise the biology of brain tumours in teenagers and young adults, improving our understanding of the disease in this age group and why improvements in outcomes have not kept up with those seen in brain tumours in both younger children and adults. The project will provide an unparalleled view of the underlying biology of these cancers, which could lead to new treatment approaches.
  • Dr Helen Bryant at the University of Sheffield will lead a study to understand how a specific biological process (the Fanconi anaemia pathyway) is seen in higher levels in some patients with high-risk neuroblastoma, and that these patients have more severe disease. The project also aims to test whether novel drugs that stop this process will increase the response of neuroblastoma to existing therapies, improving survival and providing more targeted treatments with fewer side effects.
  • Prof Ken Mills and Dr Kyle Matchett at Queen’s University Belfast will expand their drug repurposing studies to investigate the effect of combinations of repurposed drugs on acute myeloid leukaemia. The utlimate aim of the project is to find drug combinations that will improve the likelihood of treatment response and reduce the chances of treatment stopping working.

You will find more information regarding these projects, here.